Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 16NIH 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Vomiting 2Nausea 2Neuroendocrine Tumors 1Neoplasms 1Colorectal Neoplasms 1

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 330Cisplatin 277Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 211Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Has results × Ondansetron × Clear all
NCT02592707 2023-07-19

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Ipsen

Phase 1/2 Terminated
40 enrolled 37 charts
EndocrineNET

Neuroendocrine Tumors

NCT01636947 2018-09-25

KMEC

Merck Sharp & Dohme LLC

Phase 4 Completed
494 enrolled 14 charts

Nausea, Neoplasms, Vomiting

NCT00601172 2018-01-17

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

GlaxoSmithKline

Phase 3 Completed
710 enrolled 29 charts
Gastrointestinal

Nausea, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡